FDA rejects J & J application for new rheumatoid arthritis treatment

Janssen Biotech ’s biologics license application for an experimental arthritis therapy it's developing was rejected by the Food and Drug Administration Horsham-based Janssen Biotech, a subsidiary of Johnson& Johnson (NYSE: JNJ), was seeking approval for sirukumab as a treatment for moderately-to-severely active rheumatoid arthritis. The FDA said additional clinical data are needed to further evaluate the safety of the new drug candidate. “We are disappointed by this development as we feel…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news